VISTA: A Promising Target for Cancer Immunotherapy?
Marco Tagliamento,Elisa Agostinetto,Roberto Borea,Mariana Brandão,Francesca Poggio,Alfredo Addeo,Matteo Lambertini
DOI: https://doi.org/10.2147/ITT.S260429
2022-05-25
ImmunoTargets and Therapy
Abstract:Marco Tagliamento, 1, 2 Elisa Agostinetto, 3, 4 Roberto Borea, 2, 5 Mariana Brandão, 3 Francesca Poggio, 6 Alfredo Addeo, 7 Matteo Lambertini 2, 8 1 Department of Medical Oncology, Medical Oncology 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy; 2 Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genova, Italy; 3 Institut Jules Bordet and Université Libre de Bruxelles (U.L.B), Brussels, Belgium; 4 Medical Oncology and Hematology Unit, IRCCS Humanitas Clinical and Research Center and Humanitas University, Milan, Italy; 5 Department of Medical Oncology, Medical Oncology 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy; 6 Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy; 7 Oncology Department, University Hospital of Geneva, Geneva, Switzerland; 8 Department of Medical Oncology, UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy Correspondence: Marco Tagliamento Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova, Genova, Italy Tel +39 010 5558902 Email Agents targeting the B7 family co-inhibitory receptors cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein-1 (PD-1), or its ligand (PD-L1), have a pivotal role in clinical practice. V-domain Ig suppressor of T-cell activation (VISTA) is a protein highly conserved between species, with a similar amino acid sequence to the B7 family members, characterized by a particularly structural homology to PD-1. It has been counted as an emerging target within the list of novel targetable immune checkpoints in oncology. Physiologically, VISTA exerts a regulatory function on the immune system at several levels, particularly by modulating T cells activation. Its altered activity plays a role in many autoimmune diseases, and its expression has been found to be prognostically implicated in different cancer types in preclinical models. We hereby present the main evidence on the value of VISTA as an immune checkpoint in solid and hematological malignancies. We also review its value as a potential target for cancer immunotherapy, by reporting the results of Phase I and II clinical trials assessing the use of drugs targeting VISTA. The complexity of its pathway, along with some unclear biological aspects concerning its molecular interactions, currently represent a limit to the applicability of VISTA as an effective biomarker for immunotherapy in oncology. A deeper characterization of this immune checkpoint may help defining its value within immune signatures of solid and hematological malignancies, and to design future therapeutic strategies. Keywords: VISTA, immune checkpoint, immunotherapy, cancer, biomarker Immune suppression is one of the escape mechanisms adopted by cancer to overcome immune surveillance. Multiple mechanisms contribute to suppress immune cells that populate the tumor's microenvironment, both through signaling and metabolic processes. 1 The discovery of immunoreceptors and the definition of their role in modulating the immunosurveillance have become a crucial hallmark in the treatment of cancer. Tumor cells work by upregulating the role of inhibitory immunoreceptors and by downregulating that of stimulatory immunoreceptors. 1 The development of immune checkpoint inhibitors (ICIs) has represented a cornerstone in oncology. The rationale of their activity is the restoration of the immune competence by removing the breaks to antitumor immune responses, particularly by blocking inhibitory signaling pathways. 2 To date, agents targeting the B7 family co-inhibitory receptors cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein-1 (PD-1) have hired a pivotal role in clinical practice. 2 Novel pathways involving other inhibitory immunoreceptors, particularly those eliciting T cell suppression, have been discovered and studied to serve as predictive biomarkers in preclinical and clinical models. 1,3–8 Among them, lymphocyte-activation gene 3 (LAG3), 9 programmed cell death protein-ligand 2 (PD-L2), 10 B and T lymphocyte attenuator (BTLA), 11 T-cell immunoglobulin and mucin domain 3 (TIM3), 12,13 T cell immunoglobulin and ITIM domain (TIGIT), 14 B7-H3, 15 B7-H4, 16 and V-domain Ig suppressor of T-cell activation (VISTA) 17 have been described as emerging targets in the list of immune checkpoints. Moreover, neoantigens represent a promising tool for immunotherapy in oncology. They are new peptide sequences (neoepitopes) generated by non-synonymous somati -Abstract Truncated-
English Else